01—Abstract
Summary
Summary of the 8-K filed August 28, 2025. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. (NYSE: LH) filed a Form 8-K on August 28, 2025 under Item 7.01 (Regulation FD Disclosure) to announce that members of its executive management team will take part in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 7:45 am ET.
The filing furnishes a press release dated August 27, 2025 as Exhibit 99.1, which is incorporated by reference. The filing contains no financial results, guidance, or material financial figures. A live audio webcast of the fireside chat will be available through the company's Investor Relations website at ir.Labcorp.com, with a replay archived afterward.
Investors seeking management commentary on the business can use this as a scheduled opportunity to hear from executives, though the filing itself does not indicate what topics will be discussed. The press release describes Labcorp as a global laboratory services company with nearly 70,000 employees serving clients in approximately 100 countries. It states that the company supported more than 75%a of new drugs and therapeutic products approved by the FDA in 2024 and performs more than 700 million tests annually.
02—Key points
Key Highlights
- Labcorp will host a fireside chat with executive management at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 7:45 am ET.
- A live audio webcast will be available on the Investor Relations website at ir.Labcorp.com, with an archived replay afterward.
- The 8-K was filed under Item 7.01 (Regulation FD Disclosure) and contains no financial results or guidance.
- Exhibit 99.1 is a press release dated August 27, 2025, announcing the conference appearance.
- The company states it has nearly 70,000 employees serving clients in approximately 100 countries.
- The company states it supported more than 75% of new drugs and therapeutic products approved by the FDA in 2024.
- The company states it performs more than 700 million tests annually for patients worldwide.
03—Questions
Frequently Asked Questions
What is the purpose of this 8-K filing?
The filing discloses under Regulation FD that Labcorp executives will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. It does not report financial results or announce a material corporate event.
When and how can investors listen to the fireside chat?
The fireside chat is scheduled for Tuesday, September 9, 2025, at 7:45 am ET. A live audio webcast will be available through the Company Investor Relations website at ir.Labcorp.com, and the webcast will be archived for replay.
Does this filing include any financial results or guidance?
No. The filing states only the conference participation and webcast details. Its exhibit list includes a press release dated August 27, 2025 and the Inline XBRL cover page file, and the filing text contains no financial figures.
What does Labcorp say about its business in the accompanying press release?
The press release describes Labcorp as a global leader of laboratory services with nearly 70,000 employees serving clients in approximately 100 countries. It states the company supported more than 75% of new drugs and therapeutic products approved by the FDA in 2024 and performs more than 700 million tests annually.
04—Continue